Wenxue Ma
Wenxue Ma and Natalia Baran

Wenxue Ma: CD47-Targeted Therapy in Cancer Immunotherapy

Wenxue Ma, Executive Guest Editor at Cytokine and Growth Factor Reviews, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:

“A commentary entitled “CD47-targeted therapy in cancer immunotherapy: at a crossroads of promise and challenge” is now available online.

Despite a strong biological rationale, the first-generation CD47 inhibitors encountered clinical roadblocks such as anemia, limited selectivity, and modest single-agent efficacy, leading several programs to pause or terminate.

These setbacks don’t mark the end rather, they underscore the importance of precision engineering, biomarker-guided patient selection, and rational combination strategies to fully realize the therapeutic potential of CD47 blockade.”

Title: CD47-Targeted Therapy in Cancer Immunotherapy: At a Crossroads of Promise and Challenge

Authors: Xuejun Guo, Yilin Fu, Natalia Baran, Wenxue Ma

Read the Full Article on Oncology Research

Wenxue Ma: CD47-Targeted Therapy in Cancer ImmunotherapyNatalia Baran, Adjunct Assistant Professor at The University of South Dakota, Sanford School of Medicine, shared this post, adding:

“Thrilled to be part of this commentary, where we explore the rise and recent setbacks of CD47-targeted therapies in cancer.

We highlight innovative strategies: like SIRPα agents and biomarker-driven approaches, that could redefine cancer immunotherapy with safer, more precise solutions.

Thank you Prof. Wenxue Ma for inviting me to this initiative!”

More posts featuring Wenxue Ma.